01—Abstract
Summary
Summary of the 10-Q filed July 24, 2025. Cited figures are marked; the original filing is the authoritative source.
West Pharmaceutical Services, Inc. reported net sales of $766.5 milliona for the three months ended June 30, 2025, up from $702.1 million a year earlier, and $1,464.5 million for the six months, up from $1,397.5 million.
Net income was $131.8 millionb for the quarter versus $111.3 million, and diluted EPS was $1.82 versus $1.51. For the six months, net income was $221.6 million, compared with $226.6 million, and diluted EPS was $3.05 versus $3.06. Consolidated operating profit rose to $153.7 million for the quarter from $126.2 million.
Restructuring charges under the 2025 plan totaled $16.6 millionc in other expense for the six months, and the filing estimates total plan charges of $30 million to $32 million with annualized savings of $35 million to $40 million. Cash provided by operating activities was $306.5 million for the six months, up from $283.2 million, while capital expenditures fell to $146.5 million from $190.8 million. Share repurchases totaled $134.0 million for the six months, compared with $454.1 million a year earlier, and the 550,000-share program was completed in April 2025.
Cash and cash equivalents were $509.7 milliond at June 30, 2025, and total debt was $202.6 million, with $497.7 million available under the $500.0 million revolving credit facility. The company disclosed a securities class action filed May 5, 2025 in the U.S. District Court for the Eastern District of Pennsylvania on behalf of investors who acquired common stock between February 16, 2023 and February 12, 2025.
The company stated it is unable to predict the outcome or estimate potential loss. Management also noted that new U.S. tariffs are not expected to have a material impact on 2025 results.
02—Key points
Key Highlights
- Net sales rose 9.2% to $766.5 million in Q2 2025, with the Proprietary Products segment up 10.7% to $619.8 million.
- Consolidated gross profit margin expanded to 35.7% in Q2 2025 from 32.8% a year earlier, driven primarily by higher plant absorption and sales price increases.
- Diluted EPS for Q2 2025 was $1.82, up from $1.51, while six-month diluted EPS was $3.05 versus $3.06, reflecting $16.6 million of six-month restructuring charges.
- Operating cash flow for the six months was $306.5 million, up from $283.2 million, while capital expenditures declined to $146.5 million from $190.8 million.
- Share repurchases fell to $134.0 million for the six months from $454.1 million, and the April 2025 completion of the 550,000-share program was reported.
- A securities class action was filed May 5, 2025, alleging violations of Sections 10(b) and 20(a) of the Exchange Act; the company says it cannot predict the outcome.
- Total equity increased to $2,929.1 million at June 30, 2025 from $2,682.3 million at December 31, 2024, and cash rose to $509.7 million.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q2 FY2025, West Pharmaceutical Services kept $0.17.
- Revenue$766.5M100.0%
- Cost of revenue−$492.6M64.3%
- Gross profit$273.9M35.7%
- Operating costs−$120.2M15.7%
- Operating income$153.7M20.1%
- Interest, other & tax−$21.9M2.9%
- Net income$131.8M17.2%
04—Financials
Financial Highlights
Figures from 10-QQ2 FY2025filed July 24, 2025Financial Statements
Q2 FY2025 against Q2 FY2024
| Line item | Q2 FY2025Q2 FY2024 | Change |
|---|---|---|
| Revenue | $766.50M$702.10M | +9.2% |
| Cost of Revenue | $492.60M$472.10M | +4.3% |
| Gross Profit | $273.90M$230.00M | +19.1% |
| R&D Expenses | $19.10M$17.50M | +9.1% |
| SG&A Expenses | $95.90M$83.00M | +15.5% |
| Operating Income | $153.70M$126.20M | +21.8% |
| Net Income | $131.80M$111.30M | +18.4% |
| EPS (Basic) | $1.82$1.52 | +19.7% |
| EPS (Diluted) | $1.82$1.51 | +20.5% |
| Shares Outstanding (Basic) | 72.20M73.00M | −1.1% |
| Shares Outstanding (Diluted) | 72.50M73.70M | −1.6% |
05—Questions
Frequently Asked Questions
How did West Pharmaceutical perform in the second quarter of 2025?
Net sales were $766.5 million, up from $702.1 million, and net income was $131.8 million, up from $111.3 million. Operating profit was $153.7 million versus $126.2 million a year earlier.
What restructuring actions did the company take in 2025?
In January 2025 the company approved a restructuring plan to adjust its operating cost base, with expected charges of approximately $30 million to $32 million and annualized savings of $35 million to $40 million. Six-month restructuring and related charges were $16.6 million within other expense, with charges expected over roughly 24 to 36 months.
What is the status of the securities class action?
On May 5, 2025, New England Teamsters Pension Fund filed a class action in the U.S. District Court for the Eastern District of Pennsylvania. The complaint seeks unspecified damages, and the company intends to vigorously defend the case, which is in its early stages with no lead plaintiff yet appointed.
How strong is the company's liquidity and debt position?
Cash and cash equivalents were $509.7 million at June 30, 2025, and total debt was $202.6 million. Of the $500.0 million multi-currency revolving credit facility, $497.7 million was available, and the company was in compliance with all debt covenants.
How did capital allocation change in the first half of 2025?
Shares repurchased under programs totaled $134.0 million for the six months, down from $454.1 million in 2024. Capital expenditures fell to $146.5 million from $190.8 million, and dividends paid were $30.3 million.
06—Continue